O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko
{"title":"针对神经衰弱和适应障碍相关焦虑症患者的兰喹隆®最佳剂量方案：II 期临床试验","authors":"O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko","doi":"10.32756/0869-5490-2023-4-36-40","DOIUrl":null,"url":null,"abstract":"To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial\",\"authors\":\"O. Goncharov, D. Mavani, A. Ledovskikh, L. Tsukurova, M. Gavrik, I. Balaban, A. Globenko, A. Kapashin, M. Pasko\",\"doi\":\"10.32756/0869-5490-2023-4-36-40\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2023-4-36-40\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2023-4-36-40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Optimal dosage regimen of Ranquilon® for patients with anxiety associated with neurasthenia and adaptation disorders: phase II clinical trial
To determine the optimal dosing of Ranquilon® (N-(6-phenylhexanoyl)-glycyl-L-tryptophan amide) tablets (Valenta Pharm JSC) for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
